Form 4: Voyager Therapeutics Director Glenn Pierce Receives 24,000 Stock Options

Voyager Therapeutics, Inc. Director Glenn Pierce was granted 24,000 stock options with an exercise price of $3.28 as part of the company's 2025 Stock Incentive Plan.

Summary

• Glenn Pierce, a Director of Voyager Therapeutics, Inc. (VYGR), was granted 24,000 stock options.
• The stock options have an exercise price of $3.28 per share.
• The grant date and vesting commencement date for these options is June 3, 2025.
• The options are set to expire on June 3, 2035.
• Vesting of the options will occur upon the earlier of the one-year anniversary of the vesting commencement date or the date of the next annual meeting of stockholders, contingent on Mr. Pierce's continued service as a director.
• This grant was issued under the company's 2025 Stock Incentive Plan and is in accordance with its director compensation policy.

Sentiment

Score: 6

Explanation: The grant of stock options to a director is a standard compensation practice that aligns the director's interests with long-term shareholder value, reflecting routine corporate governance.

Positives

• The grant of stock options aligns the financial interests of Director Glenn Pierce with those of Voyager Therapeutics' shareholders, encouraging long-term value creation.
• The transaction is part of a pre-established 2025 Stock Incentive Plan and director compensation policy, indicating structured and transparent corporate governance practices.

Negatives

• The potential future exercise of these 24,000 stock options could lead to a minor dilution of existing shares, although this is a standard aspect of equity-based compensation.

Risks

• The vesting of the stock options is subject to the reporting person's continued service as a director; if service ceases before vesting, the unvested options may be forfeited.

Future Outlook

The stock options granted to Director Glenn Pierce are scheduled to vest upon the earlier of the one-year anniversary of the grant date (June 3, 2026) or the date of the next annual meeting of stockholders, provided his continued service as a director.

Management Comments

• The stock option was issued pursuant to the 2025 Stock Incentive Plan of Voyager Therapeutics, Inc. in accordance with its director compensation policy.

Industry Context

Granting stock options to directors is a common and widely accepted practice across publicly traded companies, particularly within the biotechnology and pharmaceutical sectors, to attract and retain qualified board members and align their long-term interests with shareholder value.

Comparison to Industry Standards

• The practice of compensating directors with stock options is a standard industry practice for publicly traded companies, including those in the biotechnology sector like Voyager Therapeutics. This aligns director incentives with company performance and shareholder returns, consistent with corporate governance norms.

Corporate Governance

Related Party Transactions

• This transaction constitutes a related party transaction, as it involves the company granting equity compensation to one of its directors, Glenn Pierce.

Stakeholder Impact

• Shareholders: Potential for minor future dilution if the options are exercised, but also improved alignment of the director's interests with long-term shareholder value.
• Director (Glenn Pierce): Receives equity-based compensation, incentivizing continued service and performance aligned with company goals.

Next Steps

• The 24,000 stock options granted to Glenn Pierce will vest upon the earlier of the one-year anniversary of the grant date or the date of the next annual meeting of stockholders, subject to his continued service as a director.

Key Dates

Keywords

Voyager Therapeutics, VYGR, Glenn Pierce, Stock Option, Director Compensation, SEC Form 4, Insider Transaction, Equity Grant, Incentive Plan, Biotechnology